The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Cytokines in pancreatic carcinoma: Correlation with phenotypic characteristics and prognosis
Abstract
BACKGROUND: Cytokines have been implicated in diverse processes that are relevant to pancreatic carcinoma, including cachexia, asthenia, and tumor growth. The objective of this study was to examine the association between serum levels of proinflammatory and antiinflammatory or angiogenic cytokines and the outcomes of patients with pancreatic carcinoma. METHODS: Serum cytokine levels were measured by enzyme‐linked immunosorbent assay from 51 patients with pancreatic carcinoma and from 48–62 healthy volunteers. Cytokine levels were compared with disease manifestations and overall survival. RESULTS: Circulating levels of vascular endothelial growth factor, tumor necrosis factor alpha, interleukin‐1α (IL‐1α), and IL‐1β were not elevated significantly in patients with pancreatic carcinoma, but levels of IL‐6, IL‐8, IL‐10, and IL‐1 receptor antagonist (IL‐1RA) were elevated significantly (P < 0.05). Cytokine levels were dichotomized based on an analysis of null Martingale residuals. Patients who had IL‐6 levels > 5.2 pg/mL or IL‐10 levels > 9.8 pg/mL had significantly worse survival compared with patients who had lower IL‐6 or IL‐10 levels (P < 0.05). IL‐8 levels were not associated with survival differences. Patients who had IL‐1RA levels < 159 pg/mL had significantly worse survival compared with patients who had higher IL‐1RA levels (P < 0.05). Higher IL‐6, IL‐10, and IL‐8 levels were associated with poor performance status and/or weight loss. In multivariate analysis, only T 4 tumors and high IL‐6 levels were selected as independent prognostic factors for poor survival. CONCLUSIONS: Circulating levels of several cytokines were high in patients with pancreatic carcinoma, and their association with weight loss and poor performance status suggested that they may be involved in these disease manifestations. Furthermore, serum cytokine levels, in particular IL‐6, may be a useful prognostic marker. Cancer 2004. © 2004 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nuclear Factor-κB — A Pivotal Transcription Factor in Chronic Inflammatory Diseases
Barnes, P. J., & Karin, M. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704103361506 · Cited by 4,669
Fiorentino, D. F., Bond, M. W., & Mosmann, T. R. (1989) · The Journal of experimental medicine · doi:10.1084/jem.170.6.2081 · Cited by 2,733
Interleukin-6 family of cytokines and gp130
Kishimoto, T., Akira, S., Narazaki, M., & Taga, T. (1995) · Blood · doi:10.1182/blood.v86.4.1243.bloodjournal8641243 · Cited by 1,272
Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes
Rousset, F., Garcia, E., Defrance, T., Péronne, C., Vezzio, N., Hsu, D. H., Kastelein, R., Moore, K. W., & Banchereau, J. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.5.1890 · Cited by 1,238
Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman’s disease
Yoshizaki, K., Matsuda, T., Nishimoto, N., Kuritani, T., Taeho, L., Aozasa, K., Nakahata, T., Kawai, H., Tagoh, H., & Komori, T. (1989) · Blood · doi:10.1182/blood.v74.4.1360.1360 · Cited by 928
Wang, W., Abbruzzese, J. L., Evans, D. B., Larry, L., Cleary, K. R., & Chiao, P. J. (1999) · PubMed · Cited by 726
Self-citationThe balance between IL-1 and IL-1Ra in disease
Arend, W. P. (2002) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(02)00020-5 · Cited by 721
Interleukin-8 and human cancer biology
Xie, K. (2001) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(01)00016-8 · Cited by 689
Evidence for the involvement of interleukin 6 in experimental cancer cachexia.
Strassmann, G., Fong, M., Kenney, J. S., & Jacob, C. O. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115767 · Cited by 658
Ly‐1 B (B‐1) cells are the main source of B cell‐derived interleukin 10
O'garra, A., Chang, R., Go, N., Hastings, R., Haughton, G., & Howard, M. (1992) · European Journal of Immunology · doi:10.1002/eji.1830220314 · Cited by 526
Cited by
NF-κB, inflammation, immunity and cancer: coming of age
Taniguchi, K., & Karin, M. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.142 · Cited by 2,679
Phase II Trial of Curcumin in Patients with Advanced Pancreatic Cancer
Dhillon, N., Aggarwal, B. B., Newman, R. A., Wolff, R. A., Kunnumakkara, A. B., Abbruzzese, J. L., Ng, C. S., Badmaev, V., & Kurzrock, R. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0024 · Cited by 1,331
Self-citationMuscle wasting in disease: molecular mechanisms and promising therapies
Cohen, S., Nathan, J. A., & Goldberg, A. L. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4467 · Cited by 1,089
Lesina, M., Kurkowski, M. U., Ludes, K., Rose-John, S., Treiber, M., Klöppel, G., Yoshimura, A., Reindl, W., Sipos, B., Akira, S., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.03.009 · Cited by 862
Obesity, Inflammation, and Cancer
Deng, T., Lyon, C. J., Bergin, S., Caligiuri, M. A., & Hsueh, W. A. (2016) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044359 · Cited by 794
Targeting interleukin-6 in inflammatory autoimmune diseases and cancers
Yao, X., Huang, J., Zhong, H., Shen, N., Faggioni, R., Fung, M., & Yao, Y. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.09.004 · Cited by 664
Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways
Schetter, A. J., Heegaard, N. H. H., & Harris, C. C. (2010) · Carcinogenesis · doi:10.1093/carcin/bgp272 · Cited by 657
Cytokines and their relationship to the symptoms and outcome of cancer
Seruga, B., Zhang, H., Bernstein, L. J., & Tannock, I. F. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2507 · Cited by 652
A Starring Role for Stellate Cells in the Pancreatic Cancer Microenvironment
Apte, M. V., Wilson, J. S., Lugea, A., & Pandol, S. J. (2013) · Gastroenterology · doi:10.1053/j.gastro.2012.11.037 · Cited by 450
The Role of the Anti-Inflammatory Cytokine Interleukin-10 in Tissue Fibrosis
Steen, E. H., Wang, X., Balaji, S., Butte, M. J., Bollyky, P. L., & Keswani, S. G. (2020) · Advances in Wound Care · doi:10.1089/wound.2019.1032 · Cited by 433
Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis
Ancrile, B., Lim, K.-H., & Counter, C. M. (2007) · Genes & Development · doi:10.1101/gad.1549407 · Cited by 422
Interleukin-10 and the immune response against cancer: a counterpoint
Mocellin, S., Marincola, F. M., & Young, H. A. (2005) · Journal of Leukocyte Biology · doi:10.1189/jlb.0705358 · Cited by 402
Interleukin‐6 and its receptor in cancer: Implications for Translational Therapeutics
Hong, D. S., Angelo, L. S., & Kurzrock, R. (2007) · Cancer · doi:10.1002/cncr.22999 · Cited by 370
Self-citationWhy not treat human cancer with interleukin-1 blockade?
Dinarello, C. A. (2010) · Cancer and Metastasis Reviews · doi:10.1007/s10555-010-9229-0 · Cited by 277
Qazi, B. S., Tang, K., & Qazi, A. (2011) · International Journal of Inflammation · doi:10.4061/2011/908468 · Cited by 272
Anti–Tumor Necrosis Factor Therapy Inhibits Pancreatic Tumor Growth and Metastasis
Egberts, J.-H., Cloosters, V., Noack, A., Schniewind, B., Thon, L., Klose, S., Kettler, B., von Forstner, C., Kneitz, C., Tepel, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5704 · Cited by 259
Inflammation and Cancer: Causes and Consequences
Moore, M. M., Chua, W., Charles, K. A., & Clarke, S. J. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.254 · Cited by 258
Kuen, J., Darowski, D., Kluge, T., & Majety, M. (2017) · PLOS ONE · doi:10.1371/journal.pone.0182039 · Cited by 192
Bharadwaj, U., Marin-Muller, C., Li, M., Chen, C., & Yao, Q. (2011) · Carcinogenesis · doi:10.1093/carcin/bgr075 · Cited by 118
Mueller, T. C., Bachmann, J., Prokopchuk, O., Friess, H., & Martignoni, M. E. (2016) · BMC Cancer · doi:10.1186/s12885-016-2121-8 · Cited by 95
“Moreover, IL-6 was shown to be significantly over-expressed in pancreatic cancer tissue, and serum levels were significantly elevated in cachectic compared to non-cachectic patients with pancreatic cancer [48, 52, 53] and prostate cancer [49].”
ResultKras and tumor immunity: friend or foe?
Cullis, J., Das, S., & Bar-Sagi, D. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031849 · Cited by 85
Serum interleukin-6 is associated with pancreatic ductal adenocarcinoma progression pattern
Kim, H. W., Lee, J.-C., Paik, K.-H., Kang, J., Kim, J., & Hwang, J.-H. (2017) · Medicine · doi:10.1097/md.0000000000005926 · Cited by 52
Metadata
- Authors
- Ebrahimi, B., Tucker, S. L., Li, D., Abbruzzese, J. L., & Kurzrock, R.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2004-11-03
- Volume
- 101
- Issue
- 12
- Pages
- 2727-2736
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1981000484
- Cited by
- 315
- References
- 50
- FWCI
- 3.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.